title: [Esmolol--beta-adrenergic blocking agent with ultrashort action].
abstract: Esmolol is a new, highly efficient, cardioselective beta-adrenergic receptor blocking agent for intravenous use only. Its action commences rapidly and its duration is very short (about 15 min). It is very quickly metabolized in the body into an inactive product, and hence its therapeutic effect can be easily controlled. Indications for its use are supraventricular tachyarrhythmias and hypertension during the perioperative period and noncompensated sinus tachycardia. Esmolol is considered as drug of choice in its indicational domain and hence it is being introduced into materia medica in the increasing number of countries. Its therapeutic range is wide. Hypotension is the most frequent side effect of esmolol, while bradycardia, congestive heart failure, hypotension and cardiogenic shock are the most important contraindications for its use.
authors.forename: T
authors.initials: T
authors.lastname: Marenović
authors.forename: M P
authors.initials: MP
authors.lastname: Stojiljković
authors.forename: M
authors.initials: M
authors.lastname: Marković
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D011412:Propanolamines / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C036604:esmolol